Bayer's SUNHARBO® (asundexian) Now Available in the United States
11/20/2026
Impact: 65
Unknown
Bayer has launched SUNHARBO® (asundexian) 50 mg tablets in the United States, where it is immediately available for order by healthcare providers and pharmacies. The drug is the first Factor XIa inhibitor approved in the U.S. and is indicated alongside antiplatelet therapy to reduce stroke risk in adults who recently experienced a non-cardioembolic ischemic stroke. The article reports no financial figures or stock-price impact.
AI summary, not financial advice
Share: